Legislation intended to ease the path to initial public offering for small companies is being put to use by life sciences companies. But while the recent legislation made it simpler to file and market IPOs, it remains unclear if the law is helping IPOs drum up more investor demand or effectively reduce the cost of compliance.
Last April, the Jumpstart Our Businesses Act was signed into law. The idea was to help improve the ability of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?